Table III.
Cox proportional hazard model of the overall survival rate of patients with breast cancer.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Factor | P-value | HR (95% CI) | P-value | HR (95% CI) |
| Age (≤60 vs. >60 years) | 0.983 | 1.007 (0.549–1.846) | 0.447 | 0.743 (0.345–1.599) |
| T (≤4 vs. >4 cm) | 0.079 | 0.547 (0.279–1.073) | 0.806 | 0.907 (0.416–1.979) |
| HER2 (negative vs. positive) | 0.591 | 0.835 (0.432–1.613) | 0.877 | 0.933 (0.390–2.236) |
| ER (negative vs. positive) | 0.115 | 1.627 (0.888–2.979) | 0.788 | 0.886 (0.365–2.147) |
| PR (negative vs. positive) | 0.204 | 1.544 (0.790–3.018) | 0.897 | 0.937 (0.351–2.502) |
| Ki67 (negative vs. positive) | 0.386 | 0.759 (0.407–1.416) | 0.747 | 0.892 (0.446–1.784) |
| AR (negative vs. positive) | 0.430 | 1.295 (0.682–2.460) | 0.553 | 1.271 (0.575–2.814) |
| Lymph node metastasis (N0 vs. N1/2/3) | 0.036 | 0.513 (0.275–0.958) | 0.027 | 0.419 (0.194–0.904) |
| MCT-4 expression (low vs. high) | 0.001 | 0.092 (0.039–0.217) | 0.001 | 0.096 (0.039–0.240) |
MCT-4, monocarboxylate transporter 4; HR, hazard ratio; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen receptor.